Guilloteau Laurence A, Laroucau Karine, Olivier Michel, Grillo Maria Jesus, Marin Clara M, Verger Jean-Michel, Blasco Jose-Maria
Laboratoire de Pathologie Infectieuse et Immunologie, Institut National de Recherche Agronomique, Centre de Tours-Nouzilly, F-37380 Nouzilly, France.
Vaccine. 2006 Apr 24;24(17):3461-8. doi: 10.1016/j.vaccine.2006.02.007. Epub 2006 Feb 20.
The CGV26 and CGV2631 strains are novel engineered Brucella melitensis Rev.1 mutant strains deleted for the bp26 gene or for both bp26 and omp31 genes, respectively, coding for proteins of diagnostic significance. The residual virulence and immunogenicity of both mutants were compared to the parental Rev.1 strain in sheep after subcutaneous or conjunctival vaccination. The deletion of the bp26 gene or both bp26 and omp31 genes had no significant effect on the intracellular survival of the Rev.1 strain in ovine macrophage cultures. The kinetics of infection induced by both mutants in sheep was similar to the Rev.1 strain, and inoculation by the subcutaneous route produced wider and more generalized infections than the conjunctival route. All strains were cleared from lymph nodes and organs within 3 months after inoculation. The CGV26 and CGV2631 mutants induced both specific systemic antibody response and lymphoproliferation in sheep. The kinetics of the responses induced by the mutants was quite similar to that of the parental Rev.1 strain, except for the intensity of the lymphoproliferative response, which was attenuated for the CGV2631 mutant. In conclusion, the residual virulence of both CGV26 and CGV2631 mutants in sheep was similar to that of the parental Rev.1 vaccine strain. These mutants induced also significant specific antibody and cell-mediated immunity in sheep and are suitable to be evaluated as potential vaccine candidates against B. melitensis and B. ovis infections in sheep.
CGV26和CGV2631菌株是新型工程化的羊种布鲁氏菌Rev.1突变株,分别缺失了编码具有诊断意义蛋白质的bp26基因或bp26和omp31基因。在皮下或结膜接种后,将这两种突变株的残余毒力和免疫原性与亲本Rev.1菌株在绵羊中进行了比较。bp26基因或bp26和omp31基因的缺失对Rev.1菌株在绵羊巨噬细胞培养物中的细胞内存活没有显著影响。两种突变株在绵羊中诱导的感染动力学与Rev.1菌株相似,皮下接种途径产生的感染比结膜途径更广泛、更普遍。接种后3个月内,所有菌株均从淋巴结和器官中清除。CGV26和CGV2631突变株在绵羊中诱导了特异性全身抗体反应和淋巴细胞增殖。突变株诱导的反应动力学与亲本Rev.1菌株非常相似,除了淋巴细胞增殖反应的强度,CGV2631突变株的该反应强度减弱。总之,CGV26和CGV2631突变株在绵羊中的残余毒力与亲本Rev.1疫苗株相似。这些突变株在绵羊中还诱导了显著的特异性抗体和细胞介导的免疫,适合作为抗绵羊羊种布鲁氏菌和绵羊布鲁氏菌感染的潜在疫苗候选物进行评估。